Related Experiment Video
Updated: Aug 6, 2025
A Unified Methodological Framework for Vestibular Schwannoma Research
Published on: June 20, 2017
Advances in Targeted Therapy for Neurofibromatosis Type 2 (NF2)-Associated Vestibular Schwannomas
Evan C Cumpston1, Steven D Rhodes2, Charles W Yates3,4
1Department of Otolaryngology-Head & Neck Surgery, Indiana University School of Medicine, Fesler Hall Suite 400 1130 W. Michigan Street, Indianapolis, IN, 46202, USA.
Purpose Of Review:
Neurofibromatosis 2 (NF2) is an autosomal-dominant genetic disorder characterized by bilateral vestibular schwannomas (VS), meningiomas, ependymomas, spinal and peripheral schwannomas, optic gliomas, and juvenile cataracts. Ongoing studies provide new insight into the role of the NF2 gene and merlin in VS tumorigenesis.
Recent Findings:
As NF2 tumor biology becomes increasingly understood, therapeutics targeting specific molecular pathways have been developed and evaluated in preclinical and clinical studies. NF2-associated VS are a source of significant morbidity with current treatments including surgery, radiation, and observation. Currently, there are no FDA-approved medical therapies for VS, and the development of selective therapeutics is a high priority. This manuscript reviews NF2 tumor biology and current therapeutics undergoing investigation for treatment of patients with VS.
